Abstract
Point mutations of bcr-abl tyrosine kinase are the most frequent causes of imatinib resistance in chronic myeloid leukaemia (CML) patients. In most CML cases with BCR-ABL mutations leading to imatinib resistance the second generation of tyrosine kinase inhibitors (TKI- e.g. nilotinib or dasatinib) may be effective. Here, we report a case of a CML patient who during imatinib treatment did not obtain clinical and cytogenetic response within 12 months of therapy. The sequencing of BCR-ABL kinase domains was performed and revealed the presence of a F359I point mutation (TTC-to-ATC nucleotide change leading to Phe-to-Ile amino acid substitution). After 1 month of nilotinib therapy a rapid progression of clinical symptoms was observed. In the presence of the F359I point mutation only dasatinib treatment overcame imatinib and nilotinib resistance.
This is a preview of subscription content, log in via an institution to check access.
References
Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, et al. 2007. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109: 4143–4150.
Jakubowska J, Czyż M, 2006. Alternatywne dla STI571 inhibitory kinazy Bcr-Abl. Postępy Hig Med. Dośw. 60: 697–706.
Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. 2007. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase-II trial. Blood 109: 5143–5150.
Kantarjian H, Talpaz M, O’Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, et al. 2004. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103: 2873–2878.
O’Hare T, Eide CA, Deininger MWN, 2007. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110: 2242–2249.
Quintás-Cardama A, Kantarjian H, Jones D, Nicaise C, O’Brien S, et al. 2007. Dasatinib (BMS-354825) is active in Philadephia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 109: 497–499.
Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD, 2007. Identification of Bcr/Abl point mutations conferring resistance to the Abl kinase inhibitor AMN107 (Nilotinib) by a random muta-genesis study. Blood 109: 5011–5015.
Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, et al. 2007. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354: 2531–2541.
Tokarski JS, Newitt JA, Chang CYJ, Cheng JD, Wittekind M, et al. 2006. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistance ABL mutants. Cancer Res 66: 5790–5797.
von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel Ch, Duyster J, 2006. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 108: 1328–1333.
Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD, 2006. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Can 94: 1765–1769.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Barańska, M., Lewandowski, K., Gniot, M. et al. Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene. J Appl Genet 49, 201–203 (2008). https://doi.org/10.1007/BF03195613
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03195613